U.S. Sickle Cell Disease Treatment Market to Reach $4.60 Billion and Europe $1.34 Billion by 2035 as Gene-Editing Therapies, Curative Pipeline Expansion, and Newborn Screening Programs Drive Demand.

Austin, United States, Sept. 04, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Sickle Cell Disease Treatment Market size was valued at USD 3.28 Billion in 2025 and is expected to reach USD 13.10 Billion by 2035, growing at a CAGR of 14.84% from 2026 to 2035. Demand is on the rise due to the increase in sickle cell disease cases around the globe, and the change in the treatment regime from symptom management to a curative approach. The United States of America Center for Medicare and Medicaid Services adopted the Cell and Gene Therapy Access Model in January 2025, whereby the access to expensive and curative treatments has been made easier through predictability of budgets for the Medicaid agencies covering advanced sickle cell disease treatment options, such as gene editing treatments.

Stem cell and gene therapies, expanded newborn screening programs, and the utilization of digital health technology are key in modernizing the sickle cell disease treatment options, courtesy of government awareness programs.


Download the Sickle Cell Disease Treatment Market Sample Report: https://www.snsinsider.com/sample-request/6917

Sickle Cell Disease Treatment Market Key Highlights

  • Market size, 2025: USD 3.28 Billion
  • Market size, 2026E: USD 3.77 Billion
  • Market forecast, 2035: USD 13.10 Billion
  • CAGR: 14.84% from 2026 to 2035
  • Largest region: North America
  • Fastest-growing region: Asia Pacific
  • Largest treatment modality: Blood transfusion, approximately 44.10% share in 2025
  • Fastest-growing treatment modality: Gene-editing therapies, approximately 17.34% CAGR
  • Largest route of administration: Oral
  • Fastest-growing route of administration: Parenteral
  • Largest age group: Adult, accounting for nearly two-fifths of market share in 2025
  • Fastest-growing age group: Pediatric
  • Largest end-user: Hospitals
  • Fastest-growing end-user: Specialty clinics

Market Relevance

The field of treatment of sickle cell disease has grown in significance within the realm of hematology since this hereditary defect in the hemoglobin results in sickling of the red blood cells, with resultant destruction, lack of adequate blood, and impairment in blood circulation. The approach to its treatment has developed from the traditional one based on the use of hydroxyurea and blood transfusions to more innovative strategies.

Sickle Cell Disease Treatment Market Overview

The market involves treatment using blood transfusion, hydroxyurea, bone marrow transplant, and gene editing treatment through oral and parenteral modes. Blood transfusion is widely used due to its availability and relative safety, and the introduction of gene editing treatment options, such as Casgevy and Lyfgenia marks the transition to the use of disease-modifying and curative treatments. The use of oral drugs is common in chronic medications, such as hydroxyurea, whereas parenteral treatment is becoming popular together with infusion and gene-editing treatment.

Strategic Market Outlook

The potential areas for expansion include the development of gene and cell therapy pipelines which will work to the advantage of those firms that can provide treatments for those patients looking for alternative treatments rather than being on symptomatic treatment throughout their lives. Another area for potential growth for firms is the expansion of treatment to emerging markets with a significant disease burden like Africa and South Asia.

The cost factor and lack of access to treatment centers are the key limiting factors. The cost of the treatment centers, such as Casgevy and Lyfgenia is significantly high, which becomes a hindrance for the health care system and the patients who have low capacity to pay for the treatments.

Sickle Cell Disease Treatment Market Regional Analysis

North America is dominating the the market due to the advanced health care system that is in place as well as increased awareness of diseases and favorable government backing, including the CMS Cell and Gene Therapy Access Model. The United States contributed about 85.10% of revenue generated in North America owing to the presence of top pharma companies in the region while Canada provided a small but steadily growing percentage.

The U.S. Sickle Cell Disease Treatment Market was valued at USD 1.14 Billion in 2025 and is expected to reach USD 4.60 Billion by 2035, growing at a CAGR of 15.00% from 2026 to 2035, supported by improved treatment access, a strong pipeline of candidate therapies, and rising collaborations to advance disease treatment.

Europe sickle cell disease treatment market is expected to grow from USD 0.39 billion in 2025 to reach USD 1.34 billion by 2035, growing at a CAGR of 13.00%. Germany holds 27.20% share of Europe revenue in 2025 due to presence of major biopharmaceutical firms and well-developed healthcare infrastructure in the country, whereas France, UK and Italy followed similar trend.

Asia Pacific was the fastest growing region across globe due to government interventions such as National Sickle Cell Anaemia Elimination Mission in India, increased screening procedures and investment in healthcare sector. India holds 36.40% share of region revenue in 2025 due to its large patient pool along with increasing number of screening and treatment programs led by the government.

Middle East & Africa: The UAE accounted for approximately 26.30% of regional revenue in 2025, supported by healthcare modernization efforts and rising demand for treatment solutions amid the Gulf States' expanding disease screening and treatment initiatives.

Latin America: Brazil led regional revenue at approximately 37.10% in 2025, supported by growing healthcare infrastructure investment, with Mexico and Argentina following a similar growth trajectory.

Buy the Sickle Cell Disease Treatment Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/6917

Sickle Cell Disease Treatment Market Segment Analysis

By Treatment Modality: Blood Transfusion holds about 44.10% market share in 2025 owing to easy availability and low risk. The gene editing therapy is the most rapidly growing segment with a CAGR of 17.34%, as people are adopting the curative approach such as Casgevy and Lyfgenia.

By Route of Administration: Oral administration held the largest share in 2025, favored for long-term medications such as hydroxyurea. Parenteral administration is the fastest-growing route, supported by rising adoption of infusion-based and gene-editing therapies.

By Age Group: The adult segment held the largest share in 2025, accounting for nearly two-fifths of total market share. The pediatric segment is the fastest-growing, supported by expanding newborn screening programmes enabling earlier disease identification.

By End-User: The hospitals segment accounted for the biggest market share in 2025 due to the facilities required for providing transfusion services and delivering gene therapy. The specialty clinics segment is the fastest growing because treatment centers keep growing.

Sickle Cell Disease Treatment Market Key Trends

  • Growing focus on curative approaches, particularly stem cell and gene therapies
  • Emerging pipeline therapies showing promise in reducing overall disease burden and improving reimbursement scenarios
  • Expanding newborn screening programmes and improved diagnostic capabilities supporting earlier intervention
  • Integration of digital health tools supporting improved disease management and patient monitoring
  • Government-led awareness campaigns and advocacy programmes expanding patient access to specialized treatment resources

Competitive Landscape

The Sickle Cell Disease Treatment Market includes established pharmaceutical leaders and gene-editing specialists, with competition centred on curative therapy development and expanding treatment center access.

In 2025, Vertex Pharmaceuticals continued expanding access to Casgevy, its gene-editing therapy developed with CRISPR Therapeutics, strengthening treatment center capacity to administer the curative intervention. Pfizer continued advancing its portfolio, including Oxbryta, for patients requiring disease-modifying therapy to reduce pain crises. Novartis continued expanding access to Adakveo, its crizanlizumab therapy, for patients seeking to reduce vaso-occlusive pain crises.

Major key players include

  • Novartis AG
  • Sanofi S.A.
  • Pfizer Inc.
  • Vertex Pharmaceuticals Incorporated
  • CRISPR Therapeutics AG
  • AstraZeneca plc
  • Eli Lilly and Company
  • bluebird bio, Inc.
  • Novo Nordisk A/S
  • Emmaus Life Sciences, Inc.
  • Fulcrum Therapeutics, Inc.
  • Editas Medicine, Inc.
  • Beam Therapeutics Inc.
  • Agios Pharmaceuticals, Inc.
  • Global Blood Therapeutics, Inc.
  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc

Explore the Complete Sickle Cell Disease Treatment Market Report: https://www.snsinsider.com/reports/sickle-cell-disease-treatment-market-6917

CONTACT: About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com